Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

NervGen Pharma: A “Blockbuster Drug” in the Making?

It has the potential to be one of the most disruptive pharmaceutical drug therapies of the modern era, especially for treating Alzheimer’s disease. And that gives it considerable “blockbuster drug” potential – a tantalising opportunity tha...
Marc Davis | June 25, 2021 |

Cracking the Code to Society’s Most Feared Disease

Even more so than cancer, it’s the one disease that we all fear the most. The thought of falling prey to Alzheimer’s disease and to the inevitable desecration of our mind is something that makes even the bravest among us shudder. ...
Marc Davis | February 7, 2020 |

Peniaphobia Prevails

(Peniaphobia: fear of poverty) This weekend, newsletter writers the world over are scrambling to explain to their paid subscribers why they are now showing losses in portfolios that were supposed to be showing gains, and especially because it was only two weeks ago t...
Streetwise Reports | March 3, 2020 |

Soliton Shares Rise on Announcement It Will Report Clinical Data at National Dermatology Conference

Soliton Inc. shares traded 10% higher today after advising that later this month it will present the data from clinical trials for its Rapid Acoustic Pulse device used in the treatment of keloid and hypertrophic scars at the American Society for Dermatologic Surgery Annual Mee...
Streetwise Reports | October 10, 2019 |

3D printing is a manufacturing game-changer

Calling all carnivores: ever thought about getting a meat printer? Of hand-crafting delectable beef steaks at home from plant proteins, that have the same texture, appearance and flavor as real meat, only without the distasteful killing part? 3D-printed steaks and chicken ...
Richard (Rick) Mills | November 15, 2019 |

Titans in Mining: An Interview with Rick Rule, Part I

The Critical Investor sits down with Rick Rule, CEO of Sprott U.S. Holdings, for a wide-ranging discussion of his more than four-decade-long involvement in the resource sector. Several months ago I thought of something different. Wouldn't it be nice to interview the...
Streetwise Reports | January 17, 2020 |

Revolutionary biopharma company makes waves across the globe

The following is a transcription of the above video, and The Market Online has edited it for clarity . The Market Online recently caught up with NurExone Biologic Inc (TSXV:NRX) , a revolutionary biopharmaceutical company developing regenerative medicine therapies,...
Lyndsay Malchuk | July 10, 2024 |

Allakos Shares Double on AK002 Phase 2 Results and Earnings

Allakos Inc. shares are soaring today as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. Clinical stage biotech company Allak...
Streetwise Reports | August 7, 2019 |

Fibrocell Science Shares Rise 60% on Acquisition News

Fibrocell Science's shares are trading up 60% today after the company announced that it agreed to be acquired by Castle Creek Holdings for $63.3 million, or $3.00 per share. Cell and gene therapy company Fibrocell Science Inc. (FCSC:NASDAQ) , which focuses on transfo...
Streetwise Reports | September 16, 2019 |

IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data

Shares of IVERIC bio opened nearly 100% higher today after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. Early this morning, gene therapy focused biopharmaceutical company IVERIC bio Inc. (I...
Streetwise Reports | October 29, 2019 |
1 2 3 4